SynthesisBMC cancer2025
Efficacy and safety of Mepitel film for radiodermatitis: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of Mepitel film on the prevention and treatment of radiodermatitis.
methodsWe conducted a systematic search across multiple databases, including PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and SinoMed Database, from their inception until August 6, 2024. We identified randomized controlled trials (RCTs) or controlled clinical trials that assessed the effects of Mepitel film on radiodermatitis. The risk of bias was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB2). Traditional meta-analysis was performed using RevMan 5.3 and Stata 14.0 software.
resultsA total of 27 studies involving 2,313 cancer patients were included. The pooled analysis indicated that Mepitel significantly reduced the incidence of radiation dermatitis (OR = 0.28, 95%CI 0.16 to 0.50, I
conclusionMepitel interventions significantly reduced RTOG grades and RISRAS scores, decreased the risk of moist desquamation, and shortened healing times for radiation-induced dermatitis in cancer patients. Further clinical studies are needed to better understand the relationship between Mepitel and radiation dermatitis in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.